Cohort profile: The Ontario HIV treatment network cohort study (OCS)

International Journal of Epidemiology

Volumn 42, Issue 2, 2013, Pages 402-411

  Rourke, Sean B ^a,b,c,d   Gardner, Sandra ^a,b   Burchell, Ann N ^a,b   Raboud, Janet ^b,e   Rueda, Sergio ^a   Bayoumi, Ahmed M ^b,c   Loutfy, Mona ^b,f   Cooper, Curtis ^g,h   Smieja, Marek ⁱ   Taylor, Darien ^j   DiPede, Tony ^a   Wobeser, Wendy ^k   Major, Carol ^a   Waring, Virginia ^a   Fisher, Mark ^a   Cairney, John ^l   Mittmann, Nicole ^b,m   Salit, Irving E ^b,e   Crouzat, Fred ^f   Gough, Kevin ^b,c   Ralph, Edward ⁿ   Sandre, Roger ^o   Kilby, Don ^g   Rachlis, Anita ^b,m   more..

^a ONTARIO HIV TREATMENT NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f Maple Leaf Medical Centre   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ HAMILTON HEALTH SCIENCES   (Canada)

^j Canadian AIDS Treatment Information Exchange   (Canada)

^k QUEEN S UNIVERSITY   (Canada)

^l MCMASTER UNIVERSITY   (Canada)

^m SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁿ ST JOSEPH S HOSPITAL   (Canada)

^o SUDBURY REGIONAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COHORT ANALYSIS; DATA ACQUISITION; DATABASE; ETHICS; HUMAN IMMUNODEFICIENCY VIRUS; QUALITY OF LIFE;

ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CLINICAL LABORATORY; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH SERVICES RESEARCH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; SEXUALLY TRANSMITTED DISEASE; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ONTARIO; POPULATION SURVEILLANCE; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; VIRAL LOAD;

CANADA; ONTARIO [CANADA];

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84877067121     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyr230     Document Type: Article

References (39)

1. McMurchy D, Challacombe L, Edmiston M et al. Gaining trust, ensuring security: the evolution of an Ontario HIV cohort study. In: Flood CM (ed.). Data Data Everywhere: Access and Accountability?. Montreal and Kingston: Queen's Policy Studies Series, McGill-Queen's University Press, 2010, pp. 1-28.
2. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2008. Ottawa: Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2009.
3. Remis RS, Swantee C, Liu J. Report on HIV/AIDS in Ontario, 2008.http://www.phs.utoronto.ca/ohemu/doc/2011/PHERO 2008_report_final_rev_Sept2010.pdf: Dalla Lana School of Public Health, University of Toronto, 2010 (3 February 2012, date last accessed).
4. Raboud JM, Abdurrahman ZB, Major C et al. Nonfinancial factors associated with decreased viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr 2005;39:327-32.
5. Deber RB, Kraetschmer N, Urowitz S, Sharpe N. Patient, consumer, client, or customer: what do people want to be called? Health Expect 2005;8:345-51.
6. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDS 2006;20:245-57.
7. Raboud J, Lesosky M, Sterling S, Phillips E, Walmsley S, Bayoumi A. An estimate of the proportion of symptoms reported in self-administered questionnaire that are captured as adverse drug events in an observational database. HIV Clin Trials 2007;8:311-19.
8. Park-Wyllie LY, Levine MA, Holbrook A et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis 2007;45:933-36.
9. Ware JE Jr, Kosinski M, Turner-Bowker D, Gandeck B. User's Manual for the SF-12v2 Health Survey. Lincoln, Rhode Island: Quality Metric Incorporated, 2002.
10. Delate T, Coons SJ. The discriminative ability of the 12-item short form health survey (SF-12) in a sample of persons infected with HIV. Clin Ther 2000;22:1112-20.
11. Kessler RC, Barker PR, Colpe LJ et al. Screening for serious mental illness in the general population. Arch Gen Pyschiatry 2003;60:184-89.
12. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993;88:791-804.
13. Justice AC, Holmes W, Gifford AL et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001;54:S77-90.
14. Neidig JL, Holmes W, Reynolds NR, Gifford AL, Zackin R, Wu AW. ACTG 5089: Development of assessment of body change distress (ABCD) questionnaire for evaluation of fat redistribution. Int Conf AIDS, Abstract no. B10609. 2002.
15. Ware J, Kosinski M, Bjorner J, Turner-Bowker D, Gandek B, Maruish M. User's Manual for the SF-36v2 Health Survey. Lincoln, RI: QualityMetric Incorporated, 2007.
16. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status using EQ-5D: a European Perspective. Dordrecht: Kluwer Academic Publishers, 2003.
17. Wu A, Revicki D, Jacobson D, Malitz F. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-93.
18. Chesney MA, Ickovics JR, Chambers DB et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000;12:255-66.
19. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1977;1:385-401.
20. Sherbourne CD, Stewart AL. The MOS Social Support Survey. Soc Sci Med 1991;32:705-14.
21. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health 2001;24:518-29.
22. Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV{thorn} youth. J Adolesc Health 2007;40:96-98.
23. Bunn J, Solomon S, Miller C, Forehand R. Measurement of stigma in people with HIV: a reexamination of the HIV stigma scale. AIDS Educ Prev 2007;19:198-208.
24. Turner RJ, Wheaton B, Lloyd DA. The epidemiology of social stress. Am Soc Rev 1995;60:104-25.
25. Pearlin L, Schooler C. The structure of coping. J Health Soc Behav 1978;19:2-21.
26. Carver C. You want to measure coping but your protocol's too long: Consider the Brief COPE. Int J Behv Med 1997;4: 92-100.
27. Wechsler, D. Manual for Wechsler Adult Intelligence Scale - Revised (WAIS-R). San Antonio: The Psychological Corporation, 1981.
28. Wechsler D. Wechsler Memory Scale. The Psychological Corporation. Harcourt Brace & Company, 1997.
29. Brandt J, Benedict RHB. Hopkins Verbal Learning Test- Revised. Odessa, FL: Psychological Assessment Resources, Inc., 2001.
30. Reitan RM, Wolfson D. Tucson, Arizona: Neuropsychology Press, 1993.
31. Raboud J, Blitz S, Walmsley S et al. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naive HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials 2011;11:340-50.
32. Raboud J, Li M, Walmsley S et al. Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav 2011;15:1397-409.
33. Diong C, Raboud JM, Li M, Cooper C. Ontario HIV Treatment Network Cohort Study Team. HIV/hepatitis C and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia. HIV Med 2011;12: 403-11.
34. Mittman N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort. Am J Clin Dermatol 2011;13:49-54.
35. Andany N, Raboud JM, Walmsley S et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials 2011;12:89-103.
36. Rueda S, Gibson K, Rourke SB et al. Mastery moderates the negative effect of stigma on depressive symptoms in people living with HIV. AIDS Behav 2011; doi: 10.1007/ s10461-010-9878-6 [Epub 11 January 2011].
37. Gibson K, Rueda S, Rourke SB et al. Mastery and coping moderate the negative effect of acute and chronic stressors on mental health-related quality of life in HIV. AIDS Patient Care STDS 2011;25:1-11.
38. Palmer AK, Klein MB, Raboud J et al. Cohort profile: The Canadian Observational Cohort Collaboration. Int J Epidemiol 2011;40:25-32.
39. Gange SJ, Kitahata MM, Saag MS et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007;36:294-301.